Allergan

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Retrieved on: 
Saturday, March 18, 2023
Neurotoxin, BA, Drug development, Columbia University Vagelos College of Physicians and Surgeons, University, Hyperhidrosis, Allergan, MBA, Uniform Securities Agent State Law Exam, Doctor of Philosophy, Aquavit, Harvard Medical School, Dermatology, Investment, Patient, Physician, Ophthalmology, FINRA, Axial, Drug discovery, Knowledge, Health, FDA, IND, Clostridium botulinum, Neurology, University of Oxford, Pharmaceutical industry, Management, MD

NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

Key Points: 
  • NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.
  • Alongside Aquavit's biosimilar program for its botulinum toxin, this will be the first in the world, indicated for palmar hyperhidrosis, approved by FDA.
  • Aquavit has been investing in proprietary delivery technologies and related intellectual property for botulinum toxin.
  • This is a strategic move that puts them ahead of the curve in the fast-growing multi-billion-dollar botulinum toxin market.

Introducing Pavise

Retrieved on: 
Thursday, March 16, 2023
Biomedical engineering, Multimedia, Research, Harvard University, DNA, Chemical engineering, JAY-Z, MIT, Massachusetts Institute of Technology, Dermatitis, NASA, Skin cancer, Science, UVB, Investment, UVA, Human, MBA, Light, Invention, Skin care, Entrepreneurship, The Wonderful Flight to the Mushroom Planet, United States Air Force Scientific Advisory Board, MIT Lincoln Laboratory, Allergan, Harvard Business School, Atopic dermatitis, Cosmetics, Online shopping, Pavise

CAMBRIDGE, Mass., March 16, 2023 /PRNewswire/ -- B.A.I. Biosciences, Inc., a new generation biotech company that creates and commercializes innovative solutions to skin health problems, announces the launch of Pavise: a catalyst for suncare innovation. As inventors of groundbreaking molecular technologies, Pavise is paving a new path with precision-crafted, broad-spectrum UV protection and photoaging defense through proprietary adaptive formulas for all skin tones and skin types.

Key Points: 
  • Biosciences, Inc., a new generation biotech company that creates and commercializes innovative solutions to skin health problems, announces the launch of Pavise: a catalyst for suncare innovation.
  • Pavise products utilize new technologies with first-to-market molecules, such as their patent-protected DiamondCore® Shield Technology, a new class of metal oxides molecules with superior safety, efficacy, and wearability.
  • Pavise scientists harnessed a high-efficiency electron shuttling mechanism to deliver superior and longer wavelength protection from UVA, UVB, and high energy Visible Light.
  • By optimizing for the highest UVA protection which defends your skin's DNA and preserves collagen, Pavise changes the way we experience suncare and prevent photoaging.

Histogen Reports Year-End 2022 Results and Provides Business Update

Retrieved on: 
Thursday, March 9, 2023
Methicillin, Trial of the century, IND, Conatus, Acquisition, HST, Medication, Pfizer, Enzyme, ABSSSI, Knee, SAN, Mortgage assumption, Research, NSF, Patient, Extracellular matrix, CCM, Interim, Staphylococcus aureus, EVP, Apoptosis, Cartilage, CSO, Inflammation, COVID-19, Insurance, Caspase, Toxicology, Sale, MRSA, Safety, Pharmaceutical industry, Cryptocurrency, Allergan

Twelve Months Ended December 31, 2022 and 2021

Key Points: 
  • Twelve Months Ended December 31, 2022 and 2021
    For the years ended December 31, 2022 and 2021, we recognized license revenues of $3.8 million and $27 thousand, respectively.
  • For the years ended December 31, 2022 and 2021, we recognized grant revenue of $0 and $0.1 million, respectively.
  • Research and development expenses for the years ended December 31, 2022 and 2021 were $5.0 million and $8.5 million, respectively.
  • General and administrative expenses for the years ended December 31, 2022 and 2021 were $9.4 million and $7.8 million, respectively.

Hyaluronic Acid Market Size Worth USD 19.87 Billion in 2032 | Emergen Research

Retrieved on: 
Tuesday, March 7, 2023
Hyaluronic acid, IgG4-related ophthalmic disease, Skin, Prevalence, Roche, Acquisition, News, Research, Elastin, Skin care, Growth, HA, USD, Kikkoman, AMD, Tissue, Arthropathy, Elective surgery, Niece and nephew, Arthritis, Eye, Zimmer Biomet, Osteoarthritis, Dietary supplement, Joint, Pain, Ophthalmology, Inflammation, Collagen, Ageing, Cosmetics, Pharmaceutical industry, Allergan

VANCOUVER, B.C., March 7, 2023 /PRNewswire/ -- The global Hyaluronic Acid market size was valued at USD 9.56 Billion in 2022 and is expected to reach valuation of USD 19.87 Billion in 2032 growing at a CAGR of 7.5% during the forecast period, according to a recent report by Emergen Research.

Key Points: 
  • VANCOUVER, B.C., March 7, 2023 /PRNewswire/ -- The global Hyaluronic Acid market size was valued at USD 9.56 Billion in 2022 and is expected to reach valuation of USD 19.87 Billion in 2032 growing at a CAGR of 7.5% during the forecast period, according to a recent report by Emergen Research.
  • The increasing awareness about the health benefits of hyaluronic acid and its widespread use in the cosmetics and healthcare industry are some of the primary factors driving the growth of the hyaluronic acid market.
  • Hyaluronic acid is used in various cosmetic products, including anti-aging creams, moisturizers, and serums, to hydrate and rejuvenate the skin.
  • One of the major factors driving the growth of the hyaluronic acid market is the increasing demand for anti-aging products.

Hyaluronic Acid Market Size Worth USD 19.87 Billion in 2032 | Emergen Research

Retrieved on: 
Tuesday, March 7, 2023
Hyaluronic acid, IgG4-related ophthalmic disease, Skin, Prevalence, Roche, Acquisition, News, Research, Elastin, Skin care, Growth, HA, USD, Kikkoman, AMD, Tissue, Arthropathy, Elective surgery, Niece and nephew, Arthritis, Eye, Zimmer Biomet, Osteoarthritis, Dietary supplement, Joint, Pain, Ophthalmology, Inflammation, Collagen, Ageing, Cosmetics, Pharmaceutical industry, Allergan

VANCOUVER, B.C., March 7, 2023 /PRNewswire/ -- The global Hyaluronic Acid market size was valued at USD 9.56 Billion in 2022 and is expected to reach valuation of USD 19.87 Billion in 2032 growing at a CAGR of 7.5% during the forecast period, according to a recent report by Emergen Research.

Key Points: 
  • VANCOUVER, B.C., March 7, 2023 /PRNewswire/ -- The global Hyaluronic Acid market size was valued at USD 9.56 Billion in 2022 and is expected to reach valuation of USD 19.87 Billion in 2032 growing at a CAGR of 7.5% during the forecast period, according to a recent report by Emergen Research.
  • The increasing awareness about the health benefits of hyaluronic acid and its widespread use in the cosmetics and healthcare industry are some of the primary factors driving the growth of the hyaluronic acid market.
  • Hyaluronic acid is used in various cosmetic products, including anti-aging creams, moisturizers, and serums, to hydrate and rejuvenate the skin.
  • One of the major factors driving the growth of the hyaluronic acid market is the increasing demand for anti-aging products.

Aadi Bioscience Announces Leadership Transition

Retrieved on: 
Friday, March 3, 2023
GW Pharmaceuticals, TSC2, Allergan, AADI, Perivascular epithelioid cell tumour, CFO, Interim, Aadi, Acquisition, Jazz Pharmaceuticals, TSC1, Executive, Patient, Management

Scott Giacobello, currently the Company's Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer and President in addition to his current responsibilities.

Key Points: 
  • Scott Giacobello, currently the Company's Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer and President in addition to his current responsibilities.
  • In addition, Neil Desai, Ph.D., the Founder of Aadi Bioscience and its President and CEO prior to Mr. Delaney, continues to serve as the Executive Chairman and a member of the Board of directors and will assist with the leadership transition.
  • Mr. Giacobello said, "I look forward to my continued work with the Aadi board and management team, executing on our mission of developing FYARRO for significant unmet needs in oncology.
  • Prior to joining Aadi in 2021, Mr. Giacobello's background included fulfilling key financial and operational roles with a long history of leadership in commercial stage growth companies.

Global Breast Implants Market Outlook & Forecast Report 2023: A $3.793 Billion Market by 2028 Featuring Key Vendors - AbbVie and Johnson & Johnson - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 1, 2023
Surgery, Health, Skin, Breast cancer, Social media, Johnson & Johnson, Breast augmentation, Cancer, Mastectomy, Immune system, Disorder, ASPS, Hospital, Breast reconstruction, Risk, Beauty, Investment, Patient, Medical tourism, Breast implant, Generation Z, Growth, Ageing, Surgeon, Ear drop, AbbVie, Breast, Scar, Woman, Breast enlargement, USD, Prevalence, Rupture, Birth control, Allergan

The "Breast Implants Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breast Implants Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global breast implants market is forecast to reach a value of $3,793.71 million by 2028 from $2,529.33 million in 2022, growing at a CAGR of 6.9%.
  • The rising mastectomy procedures and the increasing prevalence of breast cancer are driving the growth of the breast implants market.
  • Large-scale investments and funding in the global breast implants market through varied conglomerates and investment firms allow product development.

Global Cosmetic Surgery Market to Reach $142.52 Billion by 2030: Players Include Abbvie, Allergan, Bausch Health, Cynosure and Galderma - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 16, 2023
Pharmaceutical, Health, Surgery, Urbanization, Botulinum toxin, Patient, Medical tourism, Male, Revenue, Allergan, Bausch Health, FDA, Growth, Laser, Dentistry, Pharmaceutical industry, Beauty salon

To improve their cosmetic look, more people are turning to dermal fillers and non-surgical procedures like facial injectables.

Key Points: 
  • To improve their cosmetic look, more people are turning to dermal fillers and non-surgical procedures like facial injectables.
  • the number of patients receiving surgery and non-surgical cosmetic operations has increased, resulting in the growth of a sizable and appealing aesthetic medicine sector functioning abroad.
  • The launch of cutting-edge dermal fillers is anticipated to further accelerate the segment's growth in the global market.
  • The number of men having cosmetic surgery has increased as a result of growing urbanization and a decline in the societal stigma associated with men having cosmetic surgery.

Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

Retrieved on: 
Wednesday, February 15, 2023
General Health, Health, Optical, Bausch, Bausch & Lomb, Actavis, Safety, NYSE, Patient, Brent Saunders, Allergan, Bausch Health, Schering-Plough, History, Lead, Management

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023.
  • Additionally, effective upon Mr. Saunders’ appointment as chair of the Board, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board.
  • To facilitate an orderly transition, Mr. Saunders will join Bausch + Lomb on Feb. 16, 2023, in an advisory capacity, where he will work closely with Mr. Papa.
  • Mr. Saunders will return to Bausch + Lomb after having served at the Company as CEO from 2010 to 2013.

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, CCO, CGRP, Widener University Commonwealth Law School, Connecticut College, Government, Arthritis, Schizophrenia, Bipolar disorder, University, Friends, Therapy, KarXT, Migraine, Psychiatry, KRTX, Wharton School of the University of Pennsylvania, Mental health, Pharmaceutical industry, Pfizer, Allergan, Sunovion

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Will Kane as chief commercial officer (CCO), effective February 6, 2023.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Will Kane as chief commercial officer (CCO), effective February 6, 2023.
  • “The addition of Will to our executive team represents an important step as we execute on our plan to transition Karuna to a fully integrated R&D and commercial organization,” said Bill Meury, president and chief executive officer, Karuna Therapeutics.
  • Most recently, he was the executive vice president and chief commercial officer at BioXcel Therapeutics.
  • in Government from Connecticut College and an M.B.A. from the Wharton School at the University of Pennsylvania.